Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human...

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Pharmacy

Background:

• Human immunodeficiency virus (HIV) infection requires tailored antiretroviral therapy in children.
• Accurate dosing of stavudine is crucial for efficacy and safety in pediatric patients.
• Previous dosing guidelines for stavudine in children were limited, necessitating further development.

Purpose of the Study:

• To develop and validate dosing guidelines for stavudine in HIV-infected children.
• To establish weight-based dosage recommendations for pediatric stavudine administration.
• To integrate pediatric and adult pharmacokinetic data for robust guideline development.

Main Methods:

• Integrated pharmacokinetic analyses from three Phase I-II studies involving pediatric and adult patients.
• Determination of dosing guidelines using intravenous dose data (children: 0.125-2 mg/kg; adults: 0.5-1 mg/kg).
• Validation of pediatric dosing recommendations using oral exposure data (children: 1-2 mg/kg/day; adults: 0.5-1 mg/kg/day).

Main Results:

• Significant correlations found between total body clearance and demographic parameters (age, weight, body surface area) in combined pediatric and adult populations (R(2) = 0.77–0.80; P = 0.0001).
• Developed models approximated pediatric doses based on clearance and adult exposure data.
• Recommended stavudine dosage: 2 mg/kg/day for children ≤30 kg and 1 mg/kg/day (adult dose) for children >30 kg.

Conclusions:

• Established evidence-based dosing guidelines for stavudine in HIV-infected children.
• The developed guidelines provide weight-specific recommendations for pediatric stavudine therapy.
• These guidelines aim to optimize stavudine treatment in pediatric populations, considering pharmacokinetic variability.